NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free BCLI Stock Alerts $0.53 0.00 (-0.04%) (As of 03:45 PM ET) Add Compare Share Share Today's Range$0.52▼$0.5650-Day Range$0.31▼$0.7452-Week Range$0.13▼$3.34Volume248,162 shsAverage Volume969,101 shsMarket Capitalization$36.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Brainstorm Cell Therapeutics alerts: Email Address Brainstorm Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.91% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector863rd out of 908 stocksBiological Products, Except Diagnostic Industry142nd out of 147 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Brainstorm Cell Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.91% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently increased by 48.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBrainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Brainstorm Cell Therapeutics is -0.66. Previous Next 1.4 News and Social Media Coverage News SentimentBrainstorm Cell Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Brainstorm Cell Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows5 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.45% of the stock of Brainstorm Cell Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Read More BCLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCLI Stock News HeadlinesApril 23, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above Two Hundred Day Moving Average of $0.32April 17, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 17, 2024 | msn.comBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical OfficerApril 17, 2024 | msn.comBrainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55April 17, 2024 | marketwatch.comBrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical ChiefApril 11, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 11, 2024 | finance.yahoo.comBCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 11, 2024 | prnewswire.comBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 10, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 10, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 9, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 9, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 8, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Provide Update on NurOwn ProgramApril 1, 2024 | benzinga.comBrainstorm Cell: Q4 Earnings InsightsApril 1, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate UpdateMarch 25, 2024 | msn.comWhy Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 6, 2024 | finance.yahoo.comBCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…February 29, 2024 | investing.comBrainStorm details Phase 3b trial for ALS treatment NurOwnFebruary 27, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceFebruary 27, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceFebruary 25, 2024 | finance.yahoo.comBCLI Mar 2024 1.500 callFebruary 23, 2024 | marketwatch.comBrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDAFebruary 23, 2024 | msn.comBrainStorm submits SPA request to FDA for Phase 3 study designFebruary 23, 2024 | prnewswire.comBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSFebruary 16, 2024 | wsj.comBrainstorm Cell Therapeutics Inc.See More Headlines Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BCLI CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-376.40% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-6.65Miscellaneous Outstanding Shares68,340,000Free Float64,617,000Market Cap$36.34 million OptionableOptionable Beta0.28 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Chaim Lebovits (Age 53)President & Co-CEO Comp: $878.78kDr. Stacy R. Lindborg Ph.D. (Age 54)Co-Chief Executive Officer Comp: $751.08kDr. Irit Arbel DSc (Age 64)Ph.D., Co-Founder & Independent Vice Chair of the Board Ms. Alla Patlis CPA (Age 37)M.B.A., Interim CFO & Controller Comp: $130.92kMr. Uri Yablonka (Age 47)Executive VP, Chief Business Officer, Secretary & Director Comp: $247.06kDr. Daniel Offen Ph.D.Chief Scientific AdvisorMs. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government AffairsDr. Ibrahim Dagher M.D. (Age 55)Executive VP & Chief Development Officer More ExecutivesKey CompetitorsCyclo TherapeuticsNASDAQ:CYTHProtara TherapeuticsNASDAQ:TARAEstrella ImmunopharmaNASDAQ:ESLAIN8bioNASDAQ:INABCortexymeNASDAQ:CRTXView All CompetitorsInsiders & InstitutionsKingswood Wealth Advisors LLCBought 81,050 shares on 4/15/2024Ownership: 0.119%Stacy LindborgBought 11,500 shares on 9/1/2023Total: $20,355.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions BCLI Stock Analysis - Frequently Asked Questions Should I buy or sell Brainstorm Cell Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares. View BCLI analyst ratings or view top-rated stocks. How have BCLI shares performed in 2024? Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI shares have increased by 94.8% and is now trading at $0.5318. View the best growth stocks for 2024 here. Are investors shorting Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily trading volume, of 987,100 shares, the short-interest ratio is currently 2.0 days. View Brainstorm Cell Therapeutics' Short Interest. When is Brainstorm Cell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BCLI earnings forecast. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings results on Monday, April, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP). Who are Brainstorm Cell Therapeutics' major shareholders? Brainstorm Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kingswood Wealth Advisors LLC (0.12%). View institutional ownership trends. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCLI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsTrump is sounding the alarmPreserve GoldJim Cramer’s “The Biggest Drug Ever”Behind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
